An interventional study of Infant Flow and Ram Cannula in Respiratory Distress Syndrome in Premature Infants, Non Invasive Ventilation (NIV) and Nasal Injury, sponsored by University of Sao Paulo General Hospital. Recruiting at 1 site in Brazil. Open to participants aged 28 Weeks to 36 Weeks. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University of Sao Paulo General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a prospective, randomized, stratified clinical trial by gestational age with 5 arms including preterm newborns (PTNBs) with a gestational age (GA) ≥ 28 weeks, in a public hospital in northeastern Brazil.
Patients will be randomly allocated into 5 groups according to the NIV interface:
Randomization will be done using sequentially numbered, sealed, opaque envelopes containing the group allocation, separated into two boxes as per the stratification described above. Vital signs and blood pressure will be collected before the use of ventilatory support on a specific data collection form and will continue at 4-hour intervals at the following times (8:00, 12:00, 16:00, 20:00, 0:00, 4:00) until non-invasive ventilation is withdrawn.
Research Protocol
Following approval by the Ethics Committee/National Ethics Committee, the multidisciplinary team of the NICU at the Women's Hospital will attend a meeting to present the research and receive the necessary training.
Interventions
Preterm infants (PTNBs) who meet the study inclusion criteria and require ventilatory support, using Vyaire IX5® or Bellavista® mechanical ventilation devices. Humidifiers ( GT5000 , and GT5000 plus - Globaltec Med®), which do not have servo controls , will be used and adjusted according to the temperature and relative humidity control protocol of the gas delivered to the patient as follows:
Detailed description of patient randomization according to NIV interface type:
Group 1 - intervention with Infant Flow LP®, will undergo NIV via the interfaces used in the Infant Flow LP® system, according to the study protocol using the AVPM Vyaire IX5® or Bellavista®.
Group 2 - RAM® Cannula, will receive NIV with the RAM® cannula interface, according to the study protocol using the AVPM Vyaire IX5® or Bellavista®.
Group 3 - Dräger Babyflow® nasal mask , will receive NIV via the Dräger Babyflow® interface, according to the study protocol, using the AVPM Vyaire IX5® or Bellavista®.
Group 4 - Conventional binasal prongs will receive NIV with a conventional binasal prong interface ( Ventcare®) according to the study protocol using AVPM Vyaire IX5® or Bellavista®.
Group 5 - Fanem® Flexible Anatomical Binaural Prongs Non-invasive ventilation (NIV) will be administered with a flexible anatomical binasal prong-type interface, as per the study protocol, using the AVPM Vyaire IX5® or Bellavista®.
For adjusting ventilatory parameters :
Adjusting ventilatory parameters in bilevel therapy :
To adjust parameters in CPAP :
Infant Flow LP® parameters :
All patients using NIV will undergo evaluation with inspection of the nasal septum, nasal bridge, nostrils, columella, inner surface of the nostrils using a flashlight, performed on both sides, upper lip and face, points where there is contact with the interface and/or corrugated tube every 4 hours, at the following times (00h, 04h, 08h, 12h, 16h, 20h), until the device is removed.
The airways of preterm infants will be digitally photographed from a distance of 20 cm, using an auxiliary light positioned behind the camera. Facial images of the preterm infants will be taken using digital photogrammetry with an Apple® iPhone® 11 smartphone. This recording will be carried out by the researchers. The photogrammetries will be stored in a folder identified by a patient number (preserving their identity), stored in a Google® drive for this purpose, access to which is restricted to members of this research, guaranteeing the secrecy, confidentiality, and security of the participants' data, as stated in CNS Resolution No. 466 of 2012. The images will be used for analysis; there will be no disclosure of these images.
The newborn will be in a supine position, positioned in front of the examiner so that they can visualize the anterior, superior, and lateral aspects of the face and a regiãothe inside of the nostrils with a small flashlight. The assessment will be performed by the researcher as a preventive measure against pressure ulcers. If there is any doubt in the classification, they should request an evaluation from another member of the team, without disclosing their own impression. Upon identification of a stage 1 (one) lesion with hyperemia, new photographs will be taken, maintaining the same positioning, and a Neo-guard® hydrocolloid barrier dressing will be applied to the nasal region and upper lip, chosen according to the size of the nostril and the interface used, and Hypafix® will be applied to other contact points where Neo-guard® is not suitable.
Neo -guard® should be changed every seven days or if there is moisture or damage to the material.
In cases where upper airway aspiration is indicated, suction will be performed using a No. 6fr suction catheter. Cloreto de Polivinila (Non-toxic, flexible, transparent PVC with a rigorously smooth surface, featuring a rounded open end on the proximal side of the tube and two alternating holes on opposite sides (CPL medical's ®), connected to the negative pressure source, through the Ross Medical® 1000 ml - QinPot closed suction system device with drainage bag, and 0.9% saline solution may be instilled if there is difficulty in removing secretions. As per unit protocol.
Failure criteria will be considered for all groups when there is a need for:
Research Interruption Criteria
The research protocol may be interrupted if the preterm newborn does not adapt to non-invasive ventilation (NIV) or the interface, and if there is no safe material available for the application of NIV. Intolerance to the use of interfaces is considered to be indicated by: psychomotor agitation, changes in vital signs of 20% more or less than the newborn's baseline, and/or a drop in pulse oxygen saturation (SpO2) below the predicted target for the newborn.
Ethical Aspects
The study will be submitted to the Research Ethics Committee (CEP/CONEP) since the proposing institution does not have its own CEP (Hospital Inácia Pinto dos Santos), as required by Resolution 466/12 of the National Health Council (CNS), guaranteeing the well-being rights of the participants. The legal guardians of each preterm newborn will be invited to participate in the study by reading the Informed Consent Form. No research procedure will disrupt the unit's care routine, in accordance with resolutions currently in force.
There will be no disclosure of any data that could identify the research participants; data collection from medical records will be done using only the patient's registration number at the hospital unit. Research participants will be identified by sequential numbers starting from number 1 on the data collection forms, thus guaranteeing the secrecy, confidentiality, and security of the data in accordance with the General Data Protection Law.
The information collected from the patient's electronic medical record will be compiled into data collection forms and used for research results analysis. This information, necessary for the study, will be transferred to a database in the researcher's institutional email files. This research project aims to evaluate the safety and effectiveness of different interface models for non-invasive ventilation support for preterm newborns with a gestational age of 28 weeks or greater. The data collected between November 1, 2025, and November 31, 2028, will concern the child at birth and during hospitalization, including gestational age, birth weight, type of delivery, sex, length of stay, information on episodes of apnea, bradycardia, antibiotics, laboratory tests, and imaging studies.
The researchers will maintain the confidentiality of the collected data, in accordance with CNS Resolution, and will preserve the anonymity of the individuals whose data were analyzed when publishing the research results. The data will be presented in an aggregated and coded format to reinforce confidentiality and ensure participant anonymity.
Researchers are aware that the integrity of information and the privacy of research participants are the responsibility of the researchers themselves involved in the data collection process; the data collected will not be shared with individuals outside the research team. Research participants are guaranteed the right to seek redress for damages arising from the research.
Statistical analysis
Demographic characteristics and variables and pain scores, behavioral status, and respiratory discomfort will be described according to frequencies and analyzed using Student's t-test (if showing a normal distribution) or the Wilcoxon/Mann-Whitney test. Frequencies will be compared using the Chi-square test. Measures of central tendency (mean or median) and dispersion (percentiles, standard deviation) will be calculated for continuous variables. Normality will be assessed using the Shapiro-Wilk or Kolmogorov-Smirnov methods.
Analyses will be conducted to verify the association or correlation between the scores obtained and the outcomes under analysis (length of hospital stay and NICU stay; HPIV, mortality). Repeated assessment measures will be compared between groups using the Friedman test, and may be evaluated in relation to the outcomes using GEEs (Generalized Estimating Equations).
Multiple logistic regression will be used to identify potential predictors of NIV success or failure, calculating odds ratios with 95% confidence intervals (CI). The variables selected for multivariate analysis will be those that correspond to p-values less than 0.1 in the univariate analysis.
Data tabulation will be performed using Microsoft Excel® version 2010, and statistical analyses will be conducted using 'The Statistical Package for the Social Sciences' (SPSS®) version 20.0. Results will be presented as mean, standard deviation, absolute frequency, median, minimum, and maximum. A statistically significant value is considered when p ≤ 0.05.
DEMOGRAPHIC CHARACTERISTICS
The population of this trial consists of preterm newborns with a gestational age ≥ 28 weeks of both sexes, admitted to the NICU of the Inácia Pinto dos Santos Hospital.
CLINICAL SCORES AND PROGNOSES
Classification of gestational age at birth according to the World Health Organization (WHO):
Birth weight classification according to the WHO:
Apgar score:
Silverman-Andersen Bulletin .
Interpretation of results:
Brazelton's adapted sleep-wake cycle assessment scale.
Nasal and upper lip assessment for newborns on non-invasive ventilation.
Score:
Stages of nasal septum injury .
Score:
classification by Papile et al. Grade I: Hemorrhage restricted to the germinal matrix Grade II: Intraventricular hemorrhage without ventricular dilation Grade III: Intraventricular hemorrhage with ventricular dilation Grade IV: Intraparenchymal Hemorrhage
WEIGHT-STATURE VARIABLES Weight, height, head circumference (InterGrowth-prematures).
LABORATORY TESTS
The following imaging exams will be collected on a form: chest x-ray, transfontanellar ultrasound, and echocardiography; and the following laboratory tests: blood gas analysis, complete blood count, white blood cell count, and cultures collected routinely or as needed for the patient, as discussed by the multidisciplinary team.
MEDICATIONS
Data on antenatal and postnatal corticosteroid use, caffeine and aminophylline, antibiotics, and analgesic-sedative medication will be collected on a form. Duration of use, dosage, and indication for use will be recorded.
MONITORING
Data collection will be done on an individual form and at the same time interval for all groups. Care and monitoring of the newborn's vital signs on non-invasive ventilation (NIV) is continuous, with supervision performed every 4 hours, which includes:
Weaning and withdrawal from NIV (Non-Invasive Ventilation)
Ventilatory weaning, the process of withdrawing non-invasive ventilation (NIV), will begin when there is hemodynamic stability, absence of respiratory distress, absence of apneas and significant respiratory pauses, according to the following criteria:
34 studies on the registry are indexed under Respiratory Distress Syndrome In Premature Infants; 10 are open to participants now.
This study's planned enrollment of 360 is above the median of 45 across 29 interventional studies indexed under Respiratory Distress Syndrome In Premature Infants.
Browse Respiratory Distress Syndrome In Premature Infants studies →University of Sao Paulo General Hospital is the lead sponsor of 612 studies on the registry; 99 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
will undergo NIV via the interfaces used in the Infant Flow LP® system, according to the study protocol
Device: Infant Flow
will receive NIV with the RAM® cannula interface, according to the study protocol
Device: Ram Cannula
will receive NIV via the Dräger Babyflow® interface, according to the study protocol
Device: Baby Flow nasal mask
will receive NIV via a conventional binasal prong interface ( Ventcare® ) according to the study protocol
Device: Conventional binasal prongs
Non-invasive ventilation (NIV) will be administered via a flexible anatomical binasal prong-type interface, as per the study protocol
Device: Fanem Flexible Anatomical Binaural Prongs
Infant Flow LP non-invasive ventilation interface
Ram Cnnula non-invasive ventilation interface
Baby flow nasal mask non-invasive ventilation interface
Conventional binasal prongs non-invasive ventilation interface
Fanem Flexible Anatomical Binaural Prongs non-invasive ventilation interface
Incidence of Non-Invasive Ventilation (NIV) Failure
NIV failure is reported as a single composite binary outcome (Yes/No per participant) defined as the occurrence of at least one of the following standardized clinical criteria: Inspired oxygen fraction (FiO2) \> 60%; Positive end-expiratory pressure (PEEP) \> 8 cmH2O; Peak inspiratory pressure (PIP) \> 20 cmH2O or required pressure delta ≥ 12 cmH2O; Increase or lack of reduction in respiratory rate within 2 hours after NIV initiation (without fever or pain); Silverman-Andersen Score (SAS) \> 6, or recurrent apneas; SpO2/FiO2 ratio ≤ 180, or blood gas analysis with pH \< 7.22; Altered behavioral state assessed by the adapted Brazelton scale (states 5 or 6); Hemodynamic instability requiring clinical intervention; Severe cardiac arrhythmias or persistent bradycardia; Severe abdominal distension requiring NIV interruption;Worsening of underlying disease associated with deterioration of vital signs; Grade 3 nasal injury and/or upper lip facial injury score ≥ 7.
Time frame: From enrollment (Day 1) up to NIV discontinuation or hospital discharge, whichever occurs first, assessed up to 60 days (an average of 14 days).
Compare the effectiveness of the 5 VNI interfaces
Incidence of Non-Invasive Ventilation (NIV) Failure • Number of preterm infants who experience NIV failure, defined as the need for endotracheal intubation or escalation of ventilatory support according to protocol criteria.
Time frame: Up to hospital discharge, an average of 60 days.
Incidence and Severity of Interface-Related Skin Injuries
Incidence of skin and mucosal injuries caused by the interfaces or fixation devices. Severity is classified into stages: Stage 1 (non-blanchable erythema), Stage 2 (superficial erosion/partial-thickness skin loss), and Stage 3 (tissue necrosis).
Time frame: Daily during non-invasive ventilation (NIV) support, from enrollment up to NIV discontinuation (assessed up to 30 days, an average of 14 days).
Preterm Infant Behavior During Ventilatory Support
The newborn's level of alertness was assessed using an adapted version of the Brazelton Neonatal Behavioral Assessment Scale. This assessment classifies the newborn's behavioral state on a six-point ordinal scale, ranging from 1 (deep sleep) to 6 (agitated alertness). These represent categories within a single assessment, aimed at measuring the newborn's behavioral state.
Time frame: Daily during NIV support, from enrollment up to NIV discontinuation (an average of 14 days).
NIV Modes, Escalation, De-escalation, and Ventilatory Parameters
Record of NIV modes applied, escalation/de-escalation events, and parameters including PEEP, PIP (cmH2O), Inspiratory time, Rise time (seconds), Flow (L/min), and FiO2 (%).
Time frame: Continuously during NIV support, from baseline up to NIV discontinuation (an average of 14 days).
Duration of Ventilatory Support
Total number of days the infant requires non-invasive ventilatory support.
Time frame: From randomization until complete NIV weaning, assessed up to hospital discharge (an average of 60 days).
Length of Stay in NICU and Hospital
Total duration of stay in the Neonatal Intensive Care Unit (NICU) and total hospital stay.
Time frame: From date of admission/randomization through hospital discharge, assessed up to 120 days.
Incidence of Peri-Intraventricular Hemorrhage (PIVH) and Periventricular Leukomalacia (PVL)
Incidence of PIVH assessed via cranial ultrasonography according to Papile's classification: * Grade I: Hemorrhage restricted to the germinal matrix * Grade II: Intraventricular hemorrhage without ventricular dilation * Grade III: Intraventricular hemorrhage with ventricular dilation * Grade IV: Intraparenchymal hemorrhage Incidence of periventricular leukomalacia will also be recorded as present or absent.
Time frame: From enrollment up to hospital discharge (assessed up to 120 days, an average of 60 days).
Incidence of Air Leak Syndrome
Percentage of infants developing air leak complications, including pneumothorax, pneumomediastinum, and subcutaneous emphysema, confirmed by clinical assessment and/or chest radiography.
Time frame: Through NIV support duration, assessed up to hospital discharge (an average of 60 days).
Neonatal Pain Score Measured by NIPS
Pain level evaluated using the Neonatal Infant Pain Scale (NIPS). The scale assesses 6 parameters (Facial Expression, Cry, Breathing Patterns, Arms, Legs, and State of Arousal), each scored from 0 to 1 or 0 to 2, yielding a total score ranging from 0 to 7: * 0-2: Mild or no pain * 3-4: Mild to moderate pain * 5-7: Moderate to severe pain
Time frame: Evaluated every 12 hours during NIV support, from baseline up to NIV discontinuation (assessed up to 30 days, an average of 14 days).
All-Cause In-Hospital Mortality
incidence of all-cause mortality among patients who participated in the study(%)
Time frame: From enrollment through hospital discharge, assessed up to 120 days.
Incidence and Severity of Interface-Related Skin and Facial Injuries
Incidence and severity of skin and mucosal injuries caused by non-invasive ventilation (NIV) interfaces or fixation devices. Injury severity is evaluated using a dedicated 6-domain anatomical assessment tool (evaluating the tip of the nose, nasal septum, nostrils, nasal shape, nasal bridge, and upper lip). Each domain is scored from 0 (normal/no injury) to 4 (severe tissue loss/skin breakdown), yielding a cumulative total score ranging from 0 to 24. The total score is categorized as: 0 = No injury (best outcome) 1 to 4 = Mild injury 5 to 6 = Moderate injury 7 or greater = Severe injury (worst outcome)
Time frame: Daily during non-invasive ventilation (NIV) support, from enrollment up to NIV discontinuation (assessed up to 30 days, an average of 14 days)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Sep 2025 (actual). Primary completion is estimated for Nov 2028, 38 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome In Premature Infants →
University of Sao Paulo General Hospital →